MORBIDITY & MORTALITY IN HTN

主要假设：在一组高血压高危患者中，在血压控制水平相同的情况下，血管紧张素II受体拮抗剂缬沙坦在减少急性心肌梗死、充血性心力衰竭和心源性死亡率方面比钙通道阻滞剂缬沙坦更有效。次要假设：对于相同水平的血压控制，缬沙坦在降低所有死亡原因、脑血管发病率/死亡率和除急性心肌梗死/死亡率以外的冠状动脉事件方面比钙通道阻滞剂更有效。目的是进行一项研究，能够检测一组接受缬沙坦80和160 mg治疗的高血压患者（加或不加氢氯噻嗪，每日一次）与接受缬沙坦50和10 mg治疗的高血压患者（加或不加氢氯噻嗪，每日一次）之间心血管发病率和死亡率的15%差异。

Primary hypothesis In a group of high risk hypertensive patients for the same level of blood pressure control the angiotensin II receptor antagonist valsartan will be more efficacious in reducing acute myocardial infraction, congestive heart failure and cardiac mortality than the calcium channel blocker amlodipine. Secondary hypothesis For the same level of BP control valsartan will be more efficacious than the calcium channel blocker amlodipine in reducing all causes of death, cerebrovascular morbidity/mortality, and coronary events other than acute myocardial infarction/mortality. The objective is to execute a study capable of detecting a 15% difference in cardiovascular morbidity and mortality between a group of hypertensive patients treated with valsartan 80 and 160 mg, with or without the addition of hydrochlorathiazide once daily compared to a group treated with amlodipine 5 and 10 mg once daily, with or without addition of hydrochlorothiazide.